Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 12/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113324 | 0.91 | MAP2K1 (0.40) | MAP2K1MAP2K2GAARAB9AALDH1A1 | |
| SCHEMBL14402228 | 0.86 | MAP2K1 (0.39) | MAP2K1MAP2K2GAAALDH1A1 | |
| SCHEMBL9290250 | 0.80 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL1516555 | 0.79 | MAP2K1 (0.42) | MAP2K1MAP2K2POLBGAATDP1 | |
| SCHEMBL1516492 | 0.78 | MAP2K1 (0.38) | MAP2K1MAP2K2POLBGAATDP1 | |
| SCHEMBL16976162 | 0.76 | MAP2K1 (0.56) | MAP2K1MAP2K2 | |
| SCHEMBL14402383 | 0.76 | MAP2K1 (0.49) | MAP2K1MAP2K2 | |
| SCHEMBL3805944 | 0.74 | MAP2K1 (0.39) | MAP2K1MAP2K2MAPTTHRBALDH1A1 | |
| SCHEMBL3803831 | 0.72 | MAP2K1 (0.48) | MAP2K1MAP2K2 | |
| SCHEMBL14402240 | 0.72 | MAP2K1 (0.38) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897624-B2 | Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors | ARDEA BIOSCIENCES (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2009018238-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244164-A1 | PYRIDONE SULFONAMIDES AND PYRIDONE SULFAMIDES AS MEK INHIBITORS | BRAF, PDXK, MAP3K20 | MAP2K1 38/4885MAP2K2 25/4885POLB 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.